WHO invites bio prequalification
An invitation to participate in a pilot procedure for the prequalification of both branded and biosimilar rituximab and trastuzumab has been published by the World Health Organization (WHO). First announced last year (Generics bulletin, 15 September 2017, page 5) – after the WHO announced that it would start prequalifying the two oncology treatments (Generics bulletin, 12 May 2017, page 13) – the scheme, titled ‘pilot procedure for prequalification of biotherapeutic products and similar biotherapeutic products’, has been billed by the WHO as “a step forward to support national and global efforts to increase access to and the affordability of biotherapeutic products and their corresponding similar biotherapeutic products”.
You may also be interested in...
The World Health Organization has recently added further biosimilar versions of trastuzumab to its list of prequalified products, along with Roche’s original trastuzumab and rituximab brands, Herceptin and MabThera/Rituxan.
Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.